Clinical trials for BTK inhibitors have shown variable success in treating autoimmune conditions like RA, with some early-stage studies indicating modest improvement after prolonged periods (e.g., fenebrutinib’s effects becoming significant at 12 weeks). The gene discussed is BTK; the disease is rheumatoid arthritis.